{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:24:05Z","timestamp":1791228245574,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.euros.2023.09.013","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:30:25Z","timestamp":1697535025000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder"],"prefix":"10.1016","volume":"57","author":[{"given":"Roger","family":"Dmochowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gruenenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rovner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2023.09.013_b0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.euros.2023.09.013_b0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","article-title":"The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study","volume":"101","author":"Coyne","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2023.09.013_b0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2023.09.013_b0020","doi-asserted-by":"crossref","unstructured":"Fontaine C, Papworth E, Pascoe J, Hashim H. Update on the management of overactive bladder. Ther Adv Urol 2021;13:17562872211039034.","DOI":"10.1177\/17562872211039034"},{"key":"10.1016\/j.euros.2023.09.013_b0025","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2023.09.013_b0030","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2023.09.013_b0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2023.09.013_b0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.juro.2017.01.069","article-title":"The efficacy and safety of onabotulinumtoxinA or solifenacin compared with placebo in solifenacin na\u00efve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind phase 3b trial","volume":"198","author":"Herschorn","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2023.09.013_b0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SPV.0000000000000914","article-title":"Early and consistent improvements in urinary symptoms and quality of life with onabotulinumtoxinA in patients with overactive bladder and urinary incontinence: results from a randomized, placebo-controlled, phase IV clinical trial","volume":"27","author":"McCammon","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.euros.2023.09.013_b0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/toxins12030166","article-title":"Therapeutic effect of botulinum toxin A on sensory bladder disorders-from bench to bedside","volume":"12","author":"Jiang","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.euros.2023.09.013_b0055","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/nau.22642","article-title":"Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome","volume":"34","author":"Osborn","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euros.2023.09.013_b0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.tjog.2021.03.022","article-title":"Effect of aging on lower urinary tract symptoms and urodynamic parameters in women","volume":"60","author":"Lau","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.euros.2023.09.013_b0065","unstructured":"Mindardi D, editor. Urinary retention. Bristol, UK: International Continence Society; 2018. https:\/\/www.ics.org\/committees\/standardisation\/terminologydiscussions\/urinaryretention."},{"key":"10.1016\/j.euros.2023.09.013_b0070","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00192-017-3440-2","article-title":"What is the true catheterization rate after intravesical onabotulinumtoxinA injection?","volume":"29","author":"Patel","year":"2018","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euros.2023.09.013_b0075","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1080\/03007995.2018.1443061","article-title":"Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings","volume":"34","author":"Kennelly","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.euros.2023.09.013_b0080","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/jgs.13479","article-title":"Clinical meaning of a high postvoid residual: when the value of a result is less and more than one would expect","volume":"63","author":"Smith","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euros.2023.09.013_b0085","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00192-017-3271-1","article-title":"Intermittent catheterisation after botulinum toxin injections: the time to reassess our practice","volume":"28","author":"Collins","year":"2017","journal-title":"Int Urogynecol J."},{"key":"10.1016\/j.euros.2023.09.013_b0090","doi-asserted-by":"crossref","first-page":"R893","DOI":"10.1152\/ajpregu.00500.2013","article-title":"Social stress induces changes in urinary bladder function, bladder NGF content, and generalized bladder inflammation in mice","volume":"307","author":"Mingin","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.euros.2023.09.013_b0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/0253-7613.69980","article-title":"New insights into molecular targets for urinary incontinence","volume":"42","author":"Poonia","year":"2010","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.euros.2023.09.013_b0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/toxins8040091","article-title":"Intravesical onabotulinumtoxinA injection for overactive bladder patients with frailty, medical comorbidities or prior lower urinary tract surgery","volume":"8","author":"Liao","year":"2016","journal-title":"Toxins"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168323012880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168323012880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T19:46:27Z","timestamp":1715370387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168323012880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":20,"alternative-id":["S2666168323012880"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2023.09.013","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2023.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}